Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of indinavir sulfate to preparation of medicine for preventing or treating endoxemia and sepsis

A technology of indinavir sulfate and endotoxemia, applied in the field of application of indinavir sulfate in the preparation of drugs for the prevention or treatment of endotoxemia and sepsis, can solve the pharmacological problems of indinavir sulfate The effect has not been reported and other issues

Inactive Publication Date: 2014-10-29
BINZHOU MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Used alone to treat adult patients who are not clinically suitable for treatment with nucleoside or non-nucleoside reverse transcriptase inhibitors, but the pharmacological effects of indinavir sulfate in the prevention or treatment of endotoxemia and sepsis have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of indinavir sulfate to preparation of medicine for preventing or treating endoxemia and sepsis
  • Application of indinavir sulfate to preparation of medicine for preventing or treating endoxemia and sepsis
  • Application of indinavir sulfate to preparation of medicine for preventing or treating endoxemia and sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1 Preparation of Indinavir Sulfate Freeze-Dried Powder for Injection

[0012] Take 50.0g of indinavir sulfate, add 2000ml of water for injection to dissolve it, add 8g of mannitol, stir to dissolve, and ultra-filter to obtain a clear liquid without pyrogen, pour it into a 10ml vial, 2ml / bottle, press the freeze-dried powder Freeze-dried by needle process to make freeze-dried powder injections each containing 50.0 mg of indinavir sulfate.

Embodiment 2

[0013] Example 2 Preparation of Indinavir Sulfate Capsules

[0014] Weigh 200.0g of indinavir sulfate and 100.0g of sodium carboxymethyl starch, mix well and pass through a 100 mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to prepare soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, sieve with 18-mesh sieve for granulation, add 2.0g of magnesium stearate, mix well and pack into capsules, adjust the weight of the capsules to about 200mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of indinavir sulfate, and particularly relates to the application of the indinavir sulfate to inhibition of the generation and development of endoxemia and sepsis and prevention or treatment of the endoxemia and sepsis through inhibiting the expression of high-mobility group protein B1 (HMGB1). In application, the injection dosage range of the indinavir sulfate is 50mg to 2000mg, preferably 50mg to 1000mg; the oral dosage range of the indinavir sulfate is 100mg to 6000mg, preferably 200mg to 3000mg.

Description

technical field [0001] The present invention relates to indinavir sulfate inhibiting the occurrence and development of sepsis so as to prevent or treat endotoxemia and sepsis; specifically to indinavir sulfate inhibiting high mobility group protein B1 (high mobility group protein, HMGB1 ), so as to prevent or treat endotoxemia and sepsis. Background technique [0002] Sepsis (sepsis), that is, sepsis. It is a clinical syndrome caused by infection. Suppurative pathogenic bacteria invade the bloodstream and reproduce in large quantities, and spread to the whole body with the bloodstream, causing new multiple suppurative lesions in tissues and organs. Sepsis is often accompanied by the following signs: higher or lower body temperature, increased or decreased white blood cells, tachycardia, shortness of breath or abnormal increase in minute ventilation, if two or more of these symptoms appear clinically, Sepsis can be diagnosed; when it is accompanied by organ failure, it is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61P31/00A61P7/00
Inventor 蒋王林许勇吕长俊亢泽春
Owner BINZHOU MEDICAL COLLEGE